Full-Time
Application Architect
Medpace
5,001-10,000 employees
Global CRO delivering full-service clinical trials
No salary listed
Cincinnati, OH, USA
Hybrid
Hybrid work is indicated; the office-based role may allow occasional work from home after training.
Bachelor's, Master's, PhD
 Software Engineering |
|---|
Get referred to Medpace
See people who can refer or advise you
- A Bachelor's Degree or higher in Computer Science or a closely related field is required.
- At least 8 years of experience in software development is required.
- Experience with a cloud-based platform, such as Azure, is desirable.
- Experience with microservices and event-driven architectures is required.
- Expert knowledge of application programming interfaces, databases, and a server-side language such as C# is required.
- Expert understanding of front-end frameworks such as Angular is required.
- The ability to learn new technologies, systems, and processes is required.
- Strong analytical, written, and oral communication skills are required.
- Oversee the design process for application software.
- Implement and recommend viable architectural approaches that support long-term maintainability, extensibility, and interoperability of enterprise applications.
- Identify and evaluate potential risks in systems in relation to data integrity, security, and disaster recovery.
- Provide clear guidance to software development teams regarding software development patterns and proactively monitor adherence to accepted patterns.
- Contribute to shared private code repositories after aggregating feedback from software development teams.
- Maintain a versioning and governance approach for private code repositories, and ensure that applications leverage this code as appropriate.
- Build and test prototypes.
- Liaise with software development teams to craft and automate deployments.
- Conduct code reviews, security reviews, and architectural reviews, and provide solutions or improvements as necessary.
- Complete other assigned projects and responsibilities.
- Experience with a cloud-based platform such as Azure.
Medpace is a global Contract Research Organization that provides end-to-end clinical development services for pharmaceutical, biotechnology, and medical device leaders. It runs Phase I–IV trials from study design through regulatory submissions, monitoring, data management, statistics, medical writing, and final reporting. A unique feature is ownership of integrated laboratories—global central labs, a bioanalytical lab, and imaging/ECG core labs—that streamline workflows and ensure data consistency. Its goal is to help sponsors bring therapies to market efficiently by coordinating all trial activities under a physician-led, scientifically driven team.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cincinnati, Ohio
Founded
1992
Get referred to Medpace
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $707.3 million, up 17.2%, with 1.13x book-to-bill.
- Medpace raised 2026 revenue guidance to $2.805 billion-$2.885 billion on July 23, 2026.
- Zelluna chose Medpace on February 11, 2026 for its first-in-human TCR-NK trial.
What critics are saying
- Durbin v. Medpace alleges February 2026 book-to-bill inflation; discovery runs through 2027.
- Late-stage biotech funding freezes can stall clients, crushing backlog conversion within quarters.
- If cancellations stay elevated, Medpace loses trust and full-service differentiation becomes commoditized.
What makes Medpace unique
- August Troendle still runs Medpace with a physician-led, science-first operating model.
- Medpace bundles CRO, central lab, bioanalytical, imaging, and ECG services in-house.
- It specializes in small and mid-sized biotech sponsors needing full-service trial execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Unlimited Paid Time Off
Competitive Compensation and Benefits Package
Employee Health and Wellness Initiatives
Hybrid Work Options
Structured Career Paths with Opportunities for Professional Growth
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 11%Hsbc Holdings PLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 977 shares of the company’s stock, valued at approximately $518,000. Several other hedge funds and other institutional […]
Medpace reported revenues of $707.3 million in Q2, up 17.2% year on year, exceeding analyst expectations by 2.6%. The contract research organisation, which provides outsourced clinical trial management services to pharmaceutical and biotech companies, achieved the fastest revenue growth among eight drug development inputs and services stocks tracked. The company's full-year revenue guidance surpassed analyst expectations. The sector overall performed strongly, with revenues beating consensus estimates by 4.1% and share prices rising 10.5% on average since earnings. Medpace's stock rose 10.2% following the results and currently trades at $582.23. The drug development inputs and services industry benefits from stable demand as pharmaceutical companies outsource non-core functions through medium to long-term contracts.
Medpace reported second-quarter revenue of $707.3 million, exceeding analyst estimates of $689.7 million and marking 17.2% year-on-year growth. The clinical research company's GAAP profit of $4.25 per share beat consensus estimates by 6.6%. The company raised its full-year revenue guidance to $2.85 billion at the midpoint, up from $2.81 billion previously. Full-year EPS guidance of $17.60 at the midpoint came in 3.9% above analyst expectations. Medpace's stock jumped 18.6% following the results. The company's adjusted EBITDA of $153.4 million also exceeded estimates, delivering a 21.7% margin. Despite the strong performance, analysts expect revenue to remain flat over the next 12 months, suggesting potential demand challenges ahead.
Clinical research company Medpace Holdings will report its second-quarter earnings on Wednesday after market hours. The market expects Medpace's revenue to grow 14.3% year on year this quarter, in line with the 14.2% increase it recorded in the same quarter last year. In the previous quarter, Medpace reported revenues of $706.6 million, up 26.5% year on year, beating analysts' expectations. The company also exceeded EPS estimates, though its full-year EPS guidance aligned with analysts' forecasts. Analysts covering the company have generally reconfirmed their estimates over the last 30 days. Medpace shares have risen 15.8% over the past month, outperforming the life sciences tools and services segment average of 9.9%.
Turtle Creek Asset Management added Medpace Holdings, Inc. (NASDAQ:MEDP) to its portfolio in Q1 2026, citing the clinical research organisation's differentiated strategy. The company focuses on small and mid-sized biopharma companies with full-service offerings, whilst competitors mainly serve Big Pharma with lower-margin work. Medpace's clinician-led model employs full-time MDs and PhDs to develop expertise in complex therapeutic areas. The founder-run company has demonstrated strong growth and cash flow generation. Its capital allocation approach is notably opportunistic, accumulating cash when shares are expensive and repurchasing aggressively when undervalued—buying back nearly 10% of outstanding shares last year. In Q1 2026, Medpace reported revenue of $706.6 million, up 26.5% year-over-year. Shares closed at $475.07, with a market capitalisation of $13.05 billion.